Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody

Claudia Mauri, Cong-Qiu Chu, David Woodrow, Lucia Mori, Marco Londei

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We established a novel animal model for rheumatoid arthritis (RA) by following backcrossing to DBA/1 of (SWR/J × DBA/1)F1 TCR-β Tg mice, previously reported to be highly susceptible to collagen-induced arthritis. These mice evolved, upon collagen type II immunization, into a chronic arthritis that histopathologically resembles RA. The availability of such a model prompted us to study the role of CD4+ T cells throughout the evolution of disease. Here, we show that administration of nondepleting anti-CD4 not only prevented the evolution of disease but also treated established arthritis. Moreover, functional analyses of T cells isolated from anti-CD4-treated mice demonstrated that the mechanism of protection is not achieved by suppression of the Th1 population but is mediated by induction of collagen type II-specific T cell anergy. Our study suggests that: 1) CD4+ T cells have a fundamental role both in the induction and in the perpetuation of disease; 2) targeting T cells may be an appropriate therapeutic option; and 3) a suitable and well-balanced anti-CD4 treatment may be a valid approach to the control of RA.

Original languageEnglish (US)
Pages (from-to)5032-5041
Number of pages10
JournalJournal of Immunology
Volume159
Issue number10
StatePublished - Nov 15 1997
Externally publishedYes

Fingerprint

Arthritis
Monoclonal Antibodies
T-Lymphocytes
Rheumatoid Arthritis
Collagen Type II
Therapeutics
Experimental Arthritis
Inbreeding
Immunization
Animal Models
Population

ASJC Scopus subject areas

  • Immunology

Cite this

Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody. / Mauri, Claudia; Chu, Cong-Qiu; Woodrow, David; Mori, Lucia; Londei, Marco.

In: Journal of Immunology, Vol. 159, No. 10, 15.11.1997, p. 5032-5041.

Research output: Contribution to journalArticle

Mauri, C, Chu, C-Q, Woodrow, D, Mori, L & Londei, M 1997, 'Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody', Journal of Immunology, vol. 159, no. 10, pp. 5032-5041.
Mauri, Claudia ; Chu, Cong-Qiu ; Woodrow, David ; Mori, Lucia ; Londei, Marco. / Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody. In: Journal of Immunology. 1997 ; Vol. 159, No. 10. pp. 5032-5041.
@article{227f535d5429455b911f6747fd8773c1,
title = "Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody",
abstract = "We established a novel animal model for rheumatoid arthritis (RA) by following backcrossing to DBA/1 of (SWR/J × DBA/1)F1 TCR-β Tg mice, previously reported to be highly susceptible to collagen-induced arthritis. These mice evolved, upon collagen type II immunization, into a chronic arthritis that histopathologically resembles RA. The availability of such a model prompted us to study the role of CD4+ T cells throughout the evolution of disease. Here, we show that administration of nondepleting anti-CD4 not only prevented the evolution of disease but also treated established arthritis. Moreover, functional analyses of T cells isolated from anti-CD4-treated mice demonstrated that the mechanism of protection is not achieved by suppression of the Th1 population but is mediated by induction of collagen type II-specific T cell anergy. Our study suggests that: 1) CD4+ T cells have a fundamental role both in the induction and in the perpetuation of disease; 2) targeting T cells may be an appropriate therapeutic option; and 3) a suitable and well-balanced anti-CD4 treatment may be a valid approach to the control of RA.",
author = "Claudia Mauri and Cong-Qiu Chu and David Woodrow and Lucia Mori and Marco Londei",
year = "1997",
month = "11",
day = "15",
language = "English (US)",
volume = "159",
pages = "5032--5041",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Treatment of a Newly Established Transgenic Model of Chronic Arthritis with Nondepleting Anti-CD4 Monoclonal Antibody

AU - Mauri, Claudia

AU - Chu, Cong-Qiu

AU - Woodrow, David

AU - Mori, Lucia

AU - Londei, Marco

PY - 1997/11/15

Y1 - 1997/11/15

N2 - We established a novel animal model for rheumatoid arthritis (RA) by following backcrossing to DBA/1 of (SWR/J × DBA/1)F1 TCR-β Tg mice, previously reported to be highly susceptible to collagen-induced arthritis. These mice evolved, upon collagen type II immunization, into a chronic arthritis that histopathologically resembles RA. The availability of such a model prompted us to study the role of CD4+ T cells throughout the evolution of disease. Here, we show that administration of nondepleting anti-CD4 not only prevented the evolution of disease but also treated established arthritis. Moreover, functional analyses of T cells isolated from anti-CD4-treated mice demonstrated that the mechanism of protection is not achieved by suppression of the Th1 population but is mediated by induction of collagen type II-specific T cell anergy. Our study suggests that: 1) CD4+ T cells have a fundamental role both in the induction and in the perpetuation of disease; 2) targeting T cells may be an appropriate therapeutic option; and 3) a suitable and well-balanced anti-CD4 treatment may be a valid approach to the control of RA.

AB - We established a novel animal model for rheumatoid arthritis (RA) by following backcrossing to DBA/1 of (SWR/J × DBA/1)F1 TCR-β Tg mice, previously reported to be highly susceptible to collagen-induced arthritis. These mice evolved, upon collagen type II immunization, into a chronic arthritis that histopathologically resembles RA. The availability of such a model prompted us to study the role of CD4+ T cells throughout the evolution of disease. Here, we show that administration of nondepleting anti-CD4 not only prevented the evolution of disease but also treated established arthritis. Moreover, functional analyses of T cells isolated from anti-CD4-treated mice demonstrated that the mechanism of protection is not achieved by suppression of the Th1 population but is mediated by induction of collagen type II-specific T cell anergy. Our study suggests that: 1) CD4+ T cells have a fundamental role both in the induction and in the perpetuation of disease; 2) targeting T cells may be an appropriate therapeutic option; and 3) a suitable and well-balanced anti-CD4 treatment may be a valid approach to the control of RA.

UR - http://www.scopus.com/inward/record.url?scp=0031573090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031573090&partnerID=8YFLogxK

M3 - Article

VL - 159

SP - 5032

EP - 5041

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -